Calibrium Overview
- Founded
-
2012
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Calibrium General Information
Description
Developer of drugs for treatment of Diabetes. The company is developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases.
Contact Information
Primary Office
- 11711 North Meridian Street
- Suite 300
- Carmel, IN 46032
- United States
Calibrium Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 27-Aug-2015 | 00.000 | Completed | Generating Revenue | ||
| 1. Convertible Debt | 20-Dec-2013 | 00.000 | 00.000 | Completed | Generating Revenue |
Calibrium Executive Team (6)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Jaswant Gidda Ph.D | Vice President of Preclinical Development |
Calibrium Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| 5AM Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| BioCrossroads | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Frazier Healthcare Partners | PE/Buyout | Minority | 000 0000 | 000000 0 |